4.8 Article

Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 122, 期 7, 页码 2554-2566

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI58488

关键词

-

资金

  1. National Basic Research Program of China (973 Program) [2010CB912104, 2011CB910604, 2012CB8221004, 2011CB710800]
  2. National High-tech R&D Program (863 Program) [2012AA020203]
  3. State Key Project Specialized for Infectious Diseases of China [2012ZX10002-008, 2012ZX10002-012]
  4. National Natural Science Fund [30900266, 30930025, 31000348, 31000600, 31010103906, 31170766, 11179012]

向作者/读者索取更多资源

Coordinated translation initiation is coupled with cell cycle progression and cell growth, whereas excessive ribosome biogenesis and translation initiation often lead to tumor transformation and survival. Hepatocellular carcinoma (HCC) is among the most common and aggressive cancers worldwide and generally displays inherently high resistance to chemotherapeutic drugs. We found that RACK1, the receptor for activated C-kinase 1, was highly expressed in normal liver and frequently upregulated in HCC. Aberrant expression of RACK1 contributed to in vitro chemoresistance as well as in vivo tumor growth of HCC. These effects depended on ribosome localization of RACK1. Ribosomal RACK1 coupled with PKC beta II to promote the phosphorylation of eukaryotic initiation factor 4E (eIF4E), which led to preferential translation of the potent factors involved in growth and survival. Inhibition of PKC beta II or depletion of eIF4E abolished RACK1-mediated chemotherapy resistance of HCC in vitro. Our results imply that RACK1 may function as an internal factor involved in the growth and survival of HCC and suggest that targeting RACK1 may be an efficacious strategy for HCC treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据